TLSI FY2025 EPS Estimate Reduced by Cantor Fitzgerald

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) – Equities research analysts at Cantor Fitzgerald cut their FY2025 earnings per share estimates for TriSalus Life Sciences in a research report issued to clients and investors on Monday, May 19th. Cantor Fitzgerald analyst R. Osborn now expects that the company will post earnings of ($0.90) per share for the year, down from their prior forecast of ($0.56). The consensus estimate for TriSalus Life Sciences’ current full-year earnings is ($1.55) per share.

TriSalus Life Sciences (NASDAQ:TLSI) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.13). The company had revenue of $9.17 million during the quarter, compared to analyst estimates of $9.04 million. During the same period last year, the company earned ($0.60) earnings per share.

A number of other brokerages have also commented on TLSI. Roth Mkm reiterated a “buy” rating and issued a $11.00 price objective on shares of TriSalus Life Sciences in a research report on Friday, January 24th. Canaccord Genuity Group reiterated a “buy” rating and issued a $11.00 price objective on shares of TriSalus Life Sciences in a research report on Friday, March 28th. Finally, Lake Street Capital initiated coverage on TriSalus Life Sciences in a research report on Thursday, February 13th. They issued a “buy” rating and a $10.00 price objective for the company. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $10.93.

TriSalus Life Sciences Stock Up 1.3%

TriSalus Life Sciences stock opened at $5.44 on Wednesday. The stock has a 50-day simple moving average of $5.40 and a 200 day simple moving average of $5.02. The stock has a market capitalization of $175.56 million, a price-to-earnings ratio of -2.18 and a beta of 0.50. TriSalus Life Sciences has a 12-month low of $3.50 and a 12-month high of $9.95.

Hedge Funds Weigh In On TriSalus Life Sciences

Several institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC grew its position in shares of TriSalus Life Sciences by 1.9% in the 4th quarter. Geode Capital Management LLC now owns 204,137 shares of the company’s stock valued at $1,023,000 after purchasing an additional 3,710 shares during the period. Bank of America Corp DE lifted its stake in TriSalus Life Sciences by 120,471.6% in the 4th quarter. Bank of America Corp DE now owns 178,446 shares of the company’s stock valued at $894,000 after acquiring an additional 178,298 shares in the last quarter. Bridgeway Capital Management LLC lifted its stake in TriSalus Life Sciences by 333.3% in the 4th quarter. Bridgeway Capital Management LLC now owns 65,000 shares of the company’s stock valued at $326,000 after acquiring an additional 50,000 shares in the last quarter. Goldman Sachs Group Inc. bought a new stake in TriSalus Life Sciences in the 1st quarter valued at approximately $187,000. Finally, Northern Trust Corp lifted its stake in TriSalus Life Sciences by 22.7% in the 4th quarter. Northern Trust Corp now owns 32,112 shares of the company’s stock valued at $161,000 after acquiring an additional 5,936 shares in the last quarter. 2.58% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at TriSalus Life Sciences

In related news, insider Richard Marshak sold 6,597 shares of the business’s stock in a transaction that occurred on Monday, May 19th. The stock was sold at an average price of $5.18, for a total value of $34,172.46. Following the completion of the transaction, the insider now directly owns 69,101 shares in the company, valued at approximately $357,943.18. The trade was a 8.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last ninety days, insiders sold 16,125 shares of company stock worth $83,528. 27.50% of the stock is currently owned by company insiders.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.